April 22nd, 2013
The FDA, Surrogate Endpoints, and Blood Pressure Drugs
Larry Husten, PHD
In recent years the FDA has come under increasing fire for approving drugs on the basis of surrogate endpoints without any evidence of greater clinical benefit. The most famous example of this is the diabetes drug rosiglitazone. Despite strong evidence demonstrating that it was effective at lower blood glucose levels — the surrogate endpoint — serious questions […]
May 7th, 2012
Another Surrogate Endpoint Falls Short
Brahmajee Kartik Nallamothu, MD, MPH
Brahmajee Nallamothu puts into context the most recent study on the value of measuring the progression of carotid intima-media thickness.
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults